Chemoimmunotherapy is recommended for patients with non–small cell lung cancer (NSCLC) with low PD-L1 expression, but the effect of additional immunotherapy is heterogeneous in this population. To identify patients who do not benefit from the addition of immune checkpoint inhibitors (ICI) to chemotherapy, we conducted a retrospective study at 19 institutions in Japan. We analyzed 851 patients with advanced NSCLC with a PD-L1 tumor proportion score of 1% to 49% who received chemoimmunotherapy (n = 504) or chemotherapy (n = 347) between March 2017 and June 2022. After adjustment by propensity score matching, the median overall survival (OS) was 22.3 months in the chemoimmunotherapy group and 17.0 months in the chemotherapy-alone group (P = 0.01). Multivariate analysis showed that among 12 clinical factors, liver metastases (P = 0.001) and history of antibiotic use (P = 0.02) were independently associated with shorter OS in the chemoimmunotherapy group. Patients with liver metastases (OS, P = 0.4; progression-free survival, P = 0.06) or history of antimicrobial use (OS, P = 0.24; progression-free survival, P = 0.09) did not benefit from the addition of ICI to chemotherapy. Patients with a history of antimicrobial use experienced more severe pneumonitis with chemoimmunotherapy than all patients (P = 0.04). This cohort study showed that liver metastases and prior antimicrobial therapy are the most important clinical factors that attenuate the efficacy of chemoimmunotherapy in patients with low PD-L1 expression. Significance: This study shows that liver metastases and prior antibiotic use are key factors for chemoimmunotherapy in advanced NSCLC cases with low PD-L1 expression. They reduce the benefit of adding ICIs to chemotherapy, underscoring the need for new strategies to improve ICI efficacy in patients.
25 December 2025 in Respiratory Medicine Case Reports
Endobronchial hamartoma is a rare benign tumor that, when located in the central airway, can lead to airway obstruction, hemoptysis, and recurrent respiratory infections. Although various bronchoscopic treatment modalities have been reported, the application of transbronchial cryoablation has rarely been described. We report the case of a 78-year-old man with squamous cell carcinoma in the left lower lobe, in whom a pedunculated tumor was incidentally identified in the left B6 bronchus during video-assisted thoracoscopic surgery. Postoperatively, the patient's performance status declined and additional surgical resection was deemed unfeasible. Transbronchial cryoablation using a flexible cryoprobe was therefore selected as the treatment strategy. The procedure involved resection by cryo-debulking, followed by three cycles of 30-s freezing and thawing applied to each site across the entire resection margin. This intervention was safely completed under sedation without severe complications. Histopathological examination of the resected specimen confirmed the diagnosis of endobronchial hamartoma. Follow-up bronchoscopy at 6 months revealed no evidence of recurrence. This case demonstrates the potential utility of flexible cryoprobe-based cryoablation as a minimally invasive, curative approach for patients who are unsuitable candidates for surgery.
Pulmonary hyalinizing granuloma (PHG) is a rare, benign pulmonary disease characterized by dense hyalinized collagen deposition. Diagnosis is often challen